Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.
about
Immunological Evasion in GlioblastomaImmunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesEnhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case studyA highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice.Ageing and myeloid-derived suppressor cells: possible involvement in immunosenescence and age-related disease.Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancerMulticystic dedifferentiated retroperitoneal liposarcoma: tumour cyst fluid analysis and implications for managementAdjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cellsNew approaches for cancer immunotherapy.Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12.In vitro exploration of a myeloid-derived suppressor cell line as vehicle for cancer gene therapy.Myeloid cells expressing high level of CD45 are associated with a distinct activated phenotype in glioma.The Process and Regulatory Components of Inflammation in Brain Oncogenesis.Human herpesvirus 8 infection contributes to a T helper 2 immune response in men from Tobago with prostate cancer.Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth.Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine.
P2860
Q26746612-3FA1D326-5AA6-4248-B502-F5143725B9CEQ26798402-62D2C068-D12D-4B7B-AEEF-D7387B4E2583Q28084489-A8358E7C-93F8-4FEF-AC24-8562700BC7C2Q34365909-536A89DD-295E-4E53-B8EC-BACD8B487755Q34517267-94B62264-5280-40F3-B634-F236EF3A3E53Q35828574-0D42DCC9-6D22-431B-95B5-3550D03926D0Q35844190-DB5D01EF-7859-4658-8475-BFF8C1EE3E4EQ35886450-B7F33B96-F5D6-4117-BE80-9964BA52009DQ37079098-D72B5DF7-B4B6-4214-8536-4BD7DE57524DQ38454347-CBC036BA-92AC-47CF-8B79-DA4270FE34A8Q38703318-453C566A-1968-45DD-8FB5-36A2F1B2A9F4Q38730553-1D5CFDA8-2ED5-47F2-B084-536E958FF018Q38861364-1C072F41-B56C-4991-BF37-B1A10295647CQ39202332-F3519F10-0003-4DAC-A177-E73DF8E658B1Q40508590-A461DB53-C75F-47F6-9BF5-FD51DC359408Q41471218-79DC40A4-45DA-4540-B99F-AD304F8F1D77Q42124738-B2522375-7E6F-4756-90F3-01090138D62AQ42368949-F1A6FA81-765E-4116-8A08-D180E6E653AE
P2860
Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Depletion of myeloid-derived s ...... experimental malignant glioma.
@ast
Depletion of myeloid-derived s ...... experimental malignant glioma.
@en
type
label
Depletion of myeloid-derived s ...... experimental malignant glioma.
@ast
Depletion of myeloid-derived s ...... experimental malignant glioma.
@en
prefLabel
Depletion of myeloid-derived s ...... experimental malignant glioma.
@ast
Depletion of myeloid-derived s ...... experimental malignant glioma.
@en
P2093
P2860
P50
P356
P1433
P1476
Depletion of myeloid-derived s ...... experimental malignant glioma.
@en
P2093
A L Tobias
B Auffinger
M S Lesniak
P2860
P2888
P356
10.1038/CGT.2013.81
P577
2014-01-17T00:00:00Z